Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for These Side Effects

Griffin, Joshua; Holzbeierlein, Jeff M.

doi:10.1016/j.ucl.2013.01.005

Cited by 20 publications

(13 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Current treatment of immunotherapy, chemotherapy and radiotherapy have exhibited promising results and hence have been widely used as adjuvant therapies. Although these chemotherapeutic agents can achieve relatively acceptable effects, they are often insufferable on account of the strong systemic toxicity [ 8 , 9 ]. Meanwhile, chemotherapy can cause plenty of side effects to the patients [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells

Duan

2017

Cancer Cell Int

View full text Add to dashboard Cite

BackgroundThe aim of the present study was to investigate effects of Pseudomonas aeruginosa-mannose-sensitive hemagglutinin (PA-MSHA) on the inhibition of the proliferation of bladder cancer cell lines and to further define its functional mechanisms.MethodsA rat model of bladder tumor was induced by intravesical N-methyl-N nitrosourea. The dynamic growth of tumor was measured by whole-body fluorescent imaging system. Morphological analysis was observed by hematoxylin–eosin staining and microscopic examination. The expression of Caspase 3 and E-Ca were detected by immunohistochemistry technique. Macrophages were separated by flow cytometry. The expression of cytokines was measured by qRT-PCR and western blot. Apoptosis ability was conducted by means of annexin V and propidium iodide. The abilities of invasion and migration were determined by transwell migration assay and scratch assay.ResultsPA-MSHA and PA-MSHA + Fisetin groups inhibited the growth of tumor and increased the ratio of M1/M2. For one thing, PA-MSHA suppressed the invasive ability of the bladder tumor cell and promoted bladder tumor cell apoptosis. For another, it facilitated the expression of M1 cytokines and reduced expression of M2 cytokines. Furthermore, treated with PA-MSHA, mouse M1 phagocytosis rates were higher than that of M2 macrophages for bladder cancer lines.ConclusionsThe data revealed that PA-MSHA might promote apoptosis and inhibit proliferation, invasion and migration of mouse bladder cancer cells by inducing M1 polarization.

show abstract

Section: Introductionmentioning

confidence: 99%

PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells

Duan

2017

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…Although adverse effects affecting systemic coagulation are most concerning with thrombolytic therapy, local adverse effects should be considered when tPA is infused into the urinary bladder. The patient was monitored for signs of stranguria or hematuria that may have been a result of chemical cystitis, bladder wall ulceration, or local peritonitis caused by leakage of medication from the bladder . None of these effects were clinically evident in our patient; however, cystoscopy or contrast cystography would be required to completely exclude the presence of these conditions.…”

Section: Discussionmentioning

confidence: 98%

“…Recombinant tPA is considered an ideal choice due to its high molecular weight and potency, which results in low systemic absorption and reduced risk of adverse effects . The major adverse effects of intravesical tPA administration are continuous bleeding if the source of hemorrhage originates within urinary bladder and systemic fibrinolysis if there is leakage into the circulation .…”

Section: Discussionmentioning

confidence: 99%

The use of intravesicular alteplase for thrombolysis in a dog with urinary bladder thrombi

Hooi

Lemetayer

2017

J Vet Emergen Crit Care

View full text Add to dashboard Cite

show abstract

“…The American Urological Association guideline stated that the absorption of intravesical chemotherapy agents depends on their molecular weight, concentration, and lipophilic properties as well as on the surgical technique . In early‐stage bladder cancer, thiotepa (TEPA; 189 Daltons), mitomycin C (MMC; 334 Daltons), and doxorubicin (ADM; 580 Daltons) have been used . The myelosuppression rates were 18% with TEPA, 2% with MMC, and 0.8% with ADM.…”

Section: Discussionmentioning

confidence: 99%

Neutropenia and renal dysfunction due to intravesical cidofovir for virus‐associated hemorrhagic cystitis after kidney and allogenic hematopoietic stem cell transplantations

Shimizu

Kondo

Matsumoto

et al. 2019

Transplant Infectious Dis

View full text Add to dashboard Cite

Virus-associated hemorrhagic cystitis (VAHC) is a common and lifethreatening complication of allogenic hematopoietic stem cell transplantation (allo-HSCT), occurring in 8%-27% of allo-HSCT recipients with severe hematuria. 1 Late onset hemorrhagic cystitis (HC) in the post-engraftment period is associated with an adenovirus (ADV), a BK polyomavirus (BKPyV), or a JC polyomavirus (JCPyV) infection. Hemorrhagic cystitis may cause significant morbidity, prolonged hospital stay, and increased mortality. Risk factors for HC are urotoxic preconditioning regimens (cyclophosphamide, ifosfamide, busulfan and/or total body irradiation [TBI]), use of anti-thymocyte globulin, onset of acute graft versus host disease (GvHD) of grade Ⅱ or above, and the graft source (unrelated donor, cord blood transplantation, and/or human leukocyte antigen [HLA] mismatch). 2According to a recent report on 349 kidney transplant recipients followed up for 3 years, the incidence of ADV urinary infection and disseminated disease was 4.8% and 3.1%, respectively. 3 Therefore, in allo-HSCT and kidney transplant recipients, HC is a major concern.Adenoviremia and BKPyV viremia may cause severe complications such as orchitis, lymphopenia, gastroenteritis, pneumonitis, meningoencephalitis, and HC in allo-HSCT and kidney transplant recipients. In kidney transplant recipients, activities of these viruses may cause HC, leading to allograft loss and mortality.Supportive measures for this condition (eg, bladder irrigation, blood transfusion, and symptom relief) have been the standard of care for many years, and alternate treatments to eliminate viral infections have been attempted (ganciclovir, leflunomide, long-term ciprofloxacin, choreito, hyperbaric oxygen therapy, and intravenous or intravesical cidofovir). Cidofovir, the most commonly used antiviral agent for this condition, acting against ADV and BKPyV, is a cytosine purine analogue that leads to chain termination. 3While intravenous treatment has been effective, 4 myelosuppression and nephrotoxicity are major concerns. Intravenous cidofovir is not a preferred therapy in kidney transplant recipients. Therefore, to reduce nephrotoxicity, intravesical therapy was introduced. 5Based on some reports, the complete response rate was 60%, irrespective of the administration route (intravesical or intravenous). 6 AbstractWe present a patient with virus-associated hemorrhagic cystitis who underwent kidney and allogenic hematopoietic stem cell transplantations (allo-HSCT). Six months post-allo-HSCT, adenovirus hemorrhagic cystitis occurred, which has been in remission after a single dose of intravesical cidofovir. This might cause prolonged neutropenia and nephrotoxicity, suggesting cidofovir absorption in the blood. K E Y W O R D Sallogenic hematopoietic stem cell transplantation, cidofovir, intravesical, kidney transplantation, virus-associated hemorrhagic cystitis

show abstract

Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for These Side Effects

Cited by 20 publications

References 50 publications

PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells

PA-MSHA induces apoptosis and suppresses metastasis by tumor associated macrophages in bladder cancer cells

The use of intravesicular alteplase for thrombolysis in a dog with urinary bladder thrombi

Neutropenia and renal dysfunction due to intravesical cidofovir for virus‐associated hemorrhagic cystitis after kidney and allogenic hematopoietic stem cell transplantations

Contact Info

Product

Resources

About